Dynamic hyperinflation: Is it worth measuring?

Proceedings of the American Thoracic Society

Volumn 3, Issue 3, 2006, Pages 239-244

  Calverley, Peter M A ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Activity limitation; Dyspnea; Exercise capacity; Health status

Indexed keywords

BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; MARKER; OXYGEN; SALBUTAMOL;

ABDOMINAL WALL MUSCULATURE; BREATHING PATTERN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DYSPNEA; EXERCISE; EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; GAS EXCHANGE; HEALTH BEHAVIOR; HEALTH STATUS; HUMAN; HYPERINFLATION; INSPIRATORY CAPACITY; LABORATORY TEST; LUNG VOLUME; MUSCLE CONTRACTION; PHYSICAL CAPACITY; PRESERVATION; RISK FACTOR; WORKLOAD;

BRONCHODILATOR AGENTS; EXERCISE; HEALTH STATUS; HUMANS; LUNG; LUNG VOLUME MEASUREMENTS; ORGAN SIZE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY GAS EXCHANGE;

EID: 33646376444     PISSN: 15463222     EISSN: 15463222     Source Type: Journal    
DOI: 10.1513/pats.200508-084SF     Document Type: Conference Paper

References (53)

1. National Institute for Clinical Excellence. Chronic obstructive pulmonary disease: national clinical guideline onmanagement of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59:S1-S232.
2. van der Molen T, Willemse BW, Schokker S, Ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003;1:13.
3. Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002;20:799-805.
4. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002;121:1434-1440.
5. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003;167:544-549.
6. Gerardi DA, Lovett L, Benoit-Connors ML, Reardon JZ, Zuwallack RL. Variables related to increased mortality following out-patient pulmonary rehabilitation. Eur Respir J 1996;9:431-435.
7. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004;23:28-33.
8. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto-Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-1012.
9. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-1327.
10. 1-antitrypsin deficiency. Am J Respir Crit Care Med 2001;163:936-941.
11. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:972-977.
12. Man WD, Soliman MG, Gearing J, Radford SG, Rafferty GF, Gray BJ, Polkey MI, Moxham J. Symptoms and quadriceps fatigability after walking and cycling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:562-567.
13. Hamilton AL, Killian KJ, Summers E, Jones NL. Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med 1995;152:2021-2031.
14. Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997;10:417-423.
15. Bernard S, LeBlanc P, Whittom F, Carrier G, Jobin J, Belleau R, Maltais F. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:629-634.
16. Palange P, Wagner PD. The skeletal muscle in chronic respiratory diseases: summary of the ERS research seminar in Rome, Italy, February 11-12 1999. Eur Respir J 2000;15:807-815.
17. Couillard A, Maltais F, Saey D, Debigare R, Michaud A, Koechlin C, LeBlanc P, Prefaut C. Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:1664-1669.
18. Richardson RS, Sheldon J, Poole DC, Hopkins SR, Ries AL, Wagner PD. Evidence of skeletal muscle metabolic reserve during whole body exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:881-885.
19. 2 with small muscle mass exercise. Am J Respir Crit Care Med 2004;169:89-96.
20. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946.
21. Somfay A, Porszasz J, Lee SM, Casaburi R. Effect of hyperoxia on gas exchange and lactate kinetics following exercise onset in nonhypoxemic COPD patients. Chest 2002;121:393-400.
22. Spence DP, Hay JG, Carter J, Pearson MG, Calverley PM. Oxygen desaturation and breathlessness during corridor walking in chronic obstructive pulmonary disease: effect of oxitropium bromide. Thorax 1993;48:1145-1150.
23. Marciniuk DD, Gallagher CG. Clinical exercise testing in chronic airflow limitation. Med Clin North Am 1996;80:565-587.
24. Dillard TA, Piantadosi S, Rajagopal KR. Determinants of maximum exercise capacity in patients with chronic airflow obstruction. Chest 1989;96:267-271.
25. Gibson GJ. Pulmonary hyperinflation a clinical overview. Eur Respir J 1996;9:2640-2649.
26. Pride NB, Milic-Emili J. Lung mechanics. In: Calverley PMA, MacNee W, Pride NB, Rennard SI, editors. Chronic obstructive pulmonary disease. London: Arnold; 2003. pp. 151-174.
27. O'Donnell DE, Bertley JC, Chau LK, Webb KA. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med 1997;155:109-115.
28. Calverley PM, Koulouris NG. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J 2005;25:186-199.
29. Eltayara L, Becklake MR, Volta CA, Milic-Emili J. Relationship between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;154:1726-1734.
30. Diaz O, Villafranca C, Ghezzo H, Borzone G, Leiva A, Milic-Emili J, Lisboa C. Breathing pattern and gas exchange at peak exercise in COPD patients with and without tidal flow limitation at rest. Eur Respir J 2001;17:1120-1127.
31. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:770-777.
32. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004;24:86-94.
33. Yan S, Kaminski D, Sliwinski P. Reliability of inspiratory capacity for estimating end-expiratory lung volume changes during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;156:55-59.
34. O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation: the role of lung hyperinflation. Am Rev Respir Dis 1993;148:1351-1357.
35. Vogiatzis I, Nanas S, Kastanakis E, Georgiadou O, Papazahou O, Roussos C. Dynamic hyperinflation and tolerance to interval exercise in patients with advanced COPD. Eur Respir J 2004;24:385-390.
36. Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1395-1399.
37. Zakynthinos SG, Vassilakopoulos T, Zakynthinos E, Roussos C. Accurate measurement of intrinsic positive end-expiratory pressure: how to detect and correct for expiratory muscle activity. Eur Respir J 1997;10:522-529.
38. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:542-549.
39. Hay JG, Stone P, Carter J, Church S, Eyre-Brook A, Pearson MG, Woodcock AA, Calverley PM. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992;5:659-664.
40. O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur Respir J 2004;23:832-840.
41. O'Donnell DE, Bain DJ, Webb KA. Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation. Am J Respir Crit Care Med 1997;155:530-535.
42. O'Donnell DE, D'Arsigny C, Webb KA. Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:892-898.
43. Palange P, Valli G, Onorati P, Antonucci R, Paoletti P, Rosato A, Manfredi F, Serra P. Effect of heliox on lung dynamic hyperinflation, dyspnea, and exercise endurance capacity in COPD patients. J Appl Physiol 2004;97:1637-1642.
44. Laude E, Duffy N, Lawson R, Jones PW, Calverley PMA. Heliox treatment during exercise in COPD: a randomized controlled trial. Am J Respir Crit Care Med 2004;169:A468.
45. Troosters T, Casaburi R, Gosselink R, Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:19-38.
46. O'Donnell DE, McGuire M, Samis L, Webb KA. The impact of exercise reconditioning on breathlessness in severe chronic airflow limitation. Am J Respir Crit Care Med 1995;152:2005-2013.
47. Pellegrino R, Villosio C, Milanese U, Garelli G, Rodarte JR, Brusasco V. Breathing during exercise in subjects with mild-to-moderate airflow obstruction: effects of physical training. J Appl Physiol 1999;87:1697-1704.
48. Potter WA, Olafsson S, Hyatt RE. Ventilatory mechanics and expiratory flow limitation during exercise in patients with obstructive lung disease. J Clin Invest 1971;50:910-919.
49. Aliverti A, Stevenson N, Dellaca RL, Lo MA, Pedotti A, Calverley PM. Regional chest wall volumes during exercise in chronic obstructive pulmonary disease. Thorax 2004;59:210-216.
50. Man WD-C, Mustfa N, Nikoletou D, Kaul S, Hart N, Rafferty GF, Donaldson N, Polkey MI, Moxham J. The effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax 2004;59:471-476.
51. Aliverti A, Rodger K, Dellaca RL, Stevenson N, Lo Mauro A, Pedotti A, Calverley PM. The effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD. Thorax 2005;60:916-924.
52. Stevenson NJ, Calverley PM. Effect of oxygen on recovery from maximal exercise in patients with chronic obstructive pulmonary disease. Thorax 2004;59:668-672.
53. Koulouris NG, Dimopoulou I, Valta P, Finkelstein R, Cosio MG, Milic-Emili J. Detection of expiratory flow limitation during exercise in COPD patients. J Appl Physiol 1997;82:723-731. (See also comments in J Appl Physiol 1997;82:721-722.)